GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...
Zacks.com on MSN1d
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial CancerGSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...
GlobalData on MSN1d
EC approves GSK’s Jemperli-chemo combo for endometrial cancer"EC approves GSK’s Jemperli-chemo combo for endometrial cancer" was originally created and published by Pharmaceutical ...
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...
GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...
The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for ...
GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...
La Comisión Europea ha aprobado el fármaco 'JEMPERLI' (dostarlimab), de GSK, en combinación con la quimioterapia estándar (carboplatino y paclitaxel) como tratamiento de primera línea para las mujeres ...
GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...
Esta ampliación de dostarlimab, de GSK, incluye los tumores MMRp/MSS, que representan aproximadamente el 75% de los casos de ...
London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback